Press Release

August 18, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Alivus Life Sciences announces acquisition of majority stake in IQGenX. With reference to the subject mentioned above, kindly find attached media release which is self- explanatory. You are requested to take the same on record. Thanking You. Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary and Compliance Officer Encl.: As above Alivus Life Sciences Limited ( formerly Glenmark Life Sciences Limited ) Corporate Office: Registered Office: Technopolis Knowledge Park, A wingO, ffice No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri ( E), Mumba–i 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com PRESS RELEASE For Immediate dissemination Alivus Life Sciences announces acquisition of majority stake in IQGenX Mumbai, August 18, 2026: Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced the acquisition of 76% stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. Founded in October 2016, IQGenX Pharma Private Limited is a custom research organization which operates in formulation development of oral solids, sterile injectable and ophthalmic solutions for US, EU, Latin America, Middle East and other highly regulated and semi regulated markets. While APIs anchor everything that Alivus does, this acquisition enables the company to leverage its core portfolio selectively into advanced formulation development. The resultant integrated end-to-end platform will deliver deep scientific expertise across complex delivery formats, including oral solids, complex injectables and ophthalmics. Through the IQGenX platform, Alivus extends its operational footprint to include rigorous bioequivalence and stability studies, thereby enabling comprehensive regulatory filings tailored for diverse global markets. This will help significantly to expand the company’s global customer base in the generic pharmaceutical segment. Additionally, Alivus is significantly scaling up its value proposition for global CDMO customers through this expanded service platform which will cover pre-formulation studies, prototype development, process optimisation, seamless scale-up, clinical supplies and full-scale commercial manufacturing. These will be complemented with analytical development, methods validation, stability programmes and complete regulatory submission support. Furthermore, Alivus will strategically leverage IQGenX’s specialised platform alongside its own world- class API portfolio, with primary focus on Oncology, to curate a high-impact basket of differentiated, niche assets. Backed by validated, commercial-scale manufacturing capabilities, these assets are primed for strategic out-licensing across multiple geographies. The acquisition is subject to customary closing condition precedents and is expected to close by the end of the current calendar year. About Alivus Life Sciences Ltd (ALIVUS) Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited) (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 181 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW). The company’s four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE. Learn more about Alivus Life Sciences Limited on https://www.alivus.com For any further queries please contact: Soumi Rao | Senior General Manager – Corporate Communications Email: Soumi.Rao@alivus.com Mobile: 98701 96931 PRESS RELEASE For Immediate dissemination Ernst & Young LLP – Investor Relations Diwakar Pingle Email: Diwakar.Pingle@in.ey.com Sneha Salian Email: Sneha2.Salian@in.ey.com